Objectives: Gonorrhoea remains a global public health problem and the treatment options are diminishing through the emergence of gonococci resistant to most antimicrobials. Previous in vitro studies have indicated a role for Neisseria gonorrhoeae pilQ alterations in conferring resistance to antimicrobials, including penicillin. In this study, we investigated whether pilQ polymorphisms were associated with decreased susceptibility to extended-spectrum cephalosporins (ESCs) in clinical gonococcal strains.
Introduction
Gonorrhoea remains a global public health problem. Effective treatment options have rapidly diminished through the emergence and spread of Neisseria gonorrhoeae harbouring resistance to multiple classes of antimicrobials, including penicillins, tetracyclines, macrolides and quinolones. Extended-spectrum cephalosporins (ESCs), including the oral cefixime and the injectable ceftriaxone, are the last remaining options and, currently, the mainstay of treatment in most settings. However, there are now renewed concerns regarding the control of gonorrhoea, arising from recent reports of gonococci harbouring decreased in vitro susceptibility to all ESCs, and documented treatment failures of urogenital gonorrhoea using oral ESCs in Japan and Hong Kong. Accordingly, gonorrhoea may become untreatable under certain circumstances. 1 Decreased susceptibility to ESCs in N. gonorrhoeae is due to: the presence of mosaic penA, encoding an altered penicillinbinding protein (PBP) 2; alterations in the mtrR promoter, causing an overexpression of the MtrC-MtrD-MtrE efflux pump; and penB, encoding altered forms of the porin PorB1b, particularly G120K and A121D. 2 However, it has become clear that the decreased susceptibility to ESCs in N. gonorrhoeae is more complex. For example, an A501V alteration in PBP2, together with mtrR promoter deletion and penB mutations, may significantly contribute to decreased ESC susceptibility in non-mosaic penA gonococci. 3, 4 Using transformation experiments, Zhao et al. 5 showed that the gonococcal PilQ oligomer forms a pore in the outer membrane through which antimicrobials may diffuse into the periplasm, and that an E666K alteration (pilQ2) in PilQ, when present in combination with penA, mtrR and penB alterations, leads to increased resistance to penicillin and tetracycline. A previous study showed that an F595L mutation (pilQ1) in PilQ increased the susceptibility to several antimicrobials, including penicillin, providing additional evidence for the involvement of gonococcal PilQ as a route of antimicrobial entry. 6 In this study, we examined full-length pilQ nucleotide and PilQ amino acid sequences from temporally, geographically and genetically diverse N. gonorrhoeae clinical isolates representing a wide range of ceftriaxone and cefixime MICs.
Materials and methods

N. gonorrhoeae strains
A total of 63 gonococci were retrospectively selected on the basis of ceftriaxone MIC, and temporal and geographical diversity. Ceftriaxone MICs and cefixime MICs were in the range ≤0.008-0.25 and ,0.016-0.5 mg/L (Table 1) , respectively, as determined by using agar dilution (ceftriaxone) as previously described 7 and Etest (cefixime) according to the manufacturer's instructions (AB bioMérieux, Solna, Sweden). The clinical isolates examined included 13 isolates from Australia, 7 from Asia (China, 1; Hong Kong, 1; Japan, 1; Korea, 1; Mongolia, 1; Thailand, 1; and the Philippines, 1), 25 from Sweden, 4 from the UK and 5 from the USA. The years 
a Alterations in the inverted repeat in the mtrR promoter region causing an overexpression of the MtrC-MtrD-MtrE efflux pump. The most common alteration is a deletion of a single nucleotide ('A-del'). PCR and DNA sequencing DNA sequencing was performed at the Queensland Paediatric Infectious Diseases Laboratory, Brisbane, Australia (QPID-Australia) and Ö rebro University Hospital, Ö rebro, Sweden (OUH-Sweden). At QPID-Australia, pilQ sequences were amplified by PCR, as previously described, 6 and then sent for sequencing at the Australian Genome Research Facility (http://www.agrf.org.au/). NG-MASTs and penA, mtrR and penB sequence data were available for the Australian and Asian isolates and eight out of the nine WHO reference strains (n¼28) as part of previous studies. 3, 8, 9 At OUH-Sweden (examining 34 clinical isolates and WHO C), pilQ was PCR amplified using previously described primers.
6,10 NG-MAST determination and penA, mtrR and penB sequencing were performed as previously described. 8 
Sequence analysis
Alignments of the pilQ nucleotide sequences and PilQ amino acid sequences were performed with BioEdit (version 5.0.9) software and manual adjustment using N. gonorrhoeae strain FA1090 (www.genome. ou.edu/gono.html; GenBank accession number AE004969) as the reference sequence. The assignment of PilQ amino acid sequence types was based on similarities to PilQ in N. gonorrhoeae FA1090.
Statistical analysis
Data analysis was performed using the Mann-Whitney U-test. Significance was set at a P value of ,0.05.
Results
A total of 15 different pilQ nucleotide sequence types and nine different PilQ amino acid sequences (PilQ types I -IX; Figure 1 ) were observed (Table 1 ). In the alignment of the pilQ nucleotide sequences (2196 unambiguously aligned nucleotides), 62 polymorphic nucleotide sites (a ratio of 2.8 per 100 sites) were identified compared with the pilQ sequence of FA1090, comprising a 24 nucleotide deletion, a 24 nucleotide insertion and 14 single nucleotide substitutions. PilQ alterations included a combination of a 147AKQQAAAP deletion (in PilQ type IX), an 180QAATPAKQ insertion (all PilQ types, but lacking in FA1090) and seven substitutions [Q172E (PilQ type II), S341N (PilQ types V-IX), N432S (PilQ type IV), D494N (PilQ type V), G500S (PilQ type VIII), D526N (PilQ type I) and N648S (PilQ types III -VI)] (Figure 1 ). The most common PilQ type was VII (n¼ 44 isolates), followed by type VI (n¼ 9) ( Table 1 ). All other PilQ types were represented by one to three isolates only (Table 1) . By geographical origin, PilQ types V (n¼ 1), VI (n¼ 2), VII (n¼ 9) and VIII (n ¼1) were observed in Australian gonococci, and types I (n¼ 2), VI (n¼ 6) and VII (n¼ 17) were observed in the Swedish isolates. The seven Asian isolates comprised types II (China), III (Hong Kong and Thailand) and VII (Japan, Korea, Mongolia and the Philippines). The four isolates from the UK and the five isolates from the USA were all of type VII. The WHO reference strains were represented by types III (WHO C), IV (WHO L), VI (WHO K), VII (WHO G, M, N, O and P) and IX (WHO F).
The previously described E666K (pilQ2) and F595L (pilQ1) mutations were not observed in these isolates. Independent of other genetic resistance determinants (penA mosaic, mtrR promoter deletion and penB), a statistically significant association with ceftriaxone and cefixime MICs was observed for the D526N substitution only (P,0.01 and P,0.05, respectively). However, the two isolates exhibiting the D526N alteration of PilQ (PilQ type I; Table 1 and Figure 1 ) lacked all the three previously described alterations associated with reduced ESC susceptibility, and displayed low ceftriaxone and cefixime MICs (≤0.008 and ,0.016 mg/L, respectively) ( Table 1) . Consistent with previous studies, significant associations with ceftriaxone and cefixime MICs were observed for mosaic penA (P,0.001), the adenine deletion in the mtrR promoter (P,0.01 and P,0.001, respectively) and the most common penB alterations, i.e. G120K and A121D (P,0.01) ( Table 1 ).
Discussion
The results of the present study showed that there were only eight different PilQ amino acid alterations (resulting in nine divergent sequence types) in 63 temporally and geographically diverse gonococci representing a wide range of ceftriaxone and cefixime MICs, with two PilQ types (VI and VII) accounting for the majority (84%) of isolates. Accordingly, the gonococcal poreforming secretin PilQ is highly conserved for an outer membrane protein implicated in antimicrobial resistance, particularly when compared with the highly variable PorB porin. The only PilQ alteration that was significantly associated with ceftriaxone and cefixime MICs was D526N; however, both isolates harbouring this particular mutation lacked mosaic penA, as well as mtrR and penB alterations (Table 1; isolates with PilQ type I). Thus, the low MICs observed for these two isolates could be explained by the absence of these key alterations. The previously described E666K (pilQ2 5 ) and F595L (pilQ1 6 ) alterations were absent in all isolates investigated in this study.
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